Morphic Therapeutic
35 Gatehouse Drive A-2
Waltham
Massachusetts
02451
United States
Tel: 781-996-0955
Website: http://morphictx.com/
Email: info@morphictx.com
About Morphic Therapeutic
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.YEAR FOUNDED:
December 2015
LEADERSHIP:
CEO: Praveen Tipirneni, M.D.
Chief Development Officer: Alex Lugovskoy, Ph.D.
Vice President of Chemistry: Blaise Lippa, Ph.D.
Vice President of Finance and Operations: Robert Farrell, CPA
111 articles about Morphic Therapeutic
-
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
8/25/2020
Morphic Therapeutic and AbbVie announced that AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis and additional indications.
-
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
8/10/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and second quarter 2020 financial results.
-
HitGen and Morphic Extend Drug Discovery Research Collaboration
7/6/2020
HitGen Inc. announced that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic.
-
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
6/29/2020
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for mid-year and phase 1 clinical trial expected third-quarter 2020 WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a presentation highlightin
-
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
6/18/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Confe
-
Morphic to Present at the Jefferies Virtual Healthcare Conference
5/27/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a presentation at the Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Wednesday, June 3, 2020. Morphic will give an update on the Company’s progress across its portfolio of oral small mole
-
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
5/6/2020
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and first quarter 2020 financial results.
-
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
4/29/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation at the BofA Securities 2020 Health Care Conference at 3:00 p.m. ET on Wednesday, May 13, 2020
-
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
4/7/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial officer and chief operating officer.
-
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
3/17/2020
Morphic Therapeutic today announced the appointment of Peter G. Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma, Inc., where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmona
-
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
2/28/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to present at the 40th Annual Cowen Health Care Conference at 8:00 AM ET on Wednesday, March 4, 2020
-
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
2/27/2020
Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2019.
-
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
2/14/2020
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced an oral presentation today highlighting Morphic’s product candidate MO
-
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference
-
Engitix and Morphic Enter Research Collaboration to Identify ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)
12/10/2019
Engitix Ltd and Morphic Therapeutic announce that they have entered into a research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease, an intestinal fibrosis complication that affects approximately 30 per cent of Crohn’s Disease patients.
-
Morphic to Present at the Jefferies 2019 London Healthcare Conference
11/18/2019
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 1:20 p.m. GMT, in London.
-
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
11/12/2019
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, reported corporate highlights and financial results for the third quarter of 2019.
-
Schrödinger Expands Drug Discovery Partnership with Morphic Therapeutic
8/13/2019
Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger
-
Morphic Announces Pricing of Upsized Initial Public Offering
6/27/2019
Morphic Holding, Inc. announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share.
-
4 Biotech IPOs, and 2 Are Unicorns
6/27/2019
Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.